{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T22:28:30Z","timestamp":1791412110837,"version":"4.3.3"},"reference-count":137,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2016,1,1]],"date-time":"2016-01-01T00:00:00Z","timestamp":1451606400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"GILS, the Italian Group Against Systemic Sclerosis"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Autoimmunity Reviews"],"published-print":{"date-parts":[[2016,1]]},"DOI":"10.1016\/j.autrev.2015.10.001","type":"journal-article","created":{"date-parts":[[2015,10,16]],"date-time":"2015-10-16T10:34:48Z","timestamp":1444991688000},"page":"102-109","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":25,"title":["Anti-centromere protein A antibodies in systemic sclerosis: Significance and origin"],"prefix":"10.1016","volume":"15","author":[{"given":"Federico","family":"Perosa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcella","family":"Prete","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Di Lernia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmela","family":"Ostuni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elvira","family":"Favoino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriele","family":"Valentini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.autrev.2015.10.001_bb0005","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1172\/JCI31139","article-title":"Systemic sclerosis: a prototypic multisystem fibrotic disorder","volume":"117","author":"Varga","year":"2007","journal-title":"J Clin Invest"},{"key":"10.1016\/j.autrev.2015.10.001_bb0010","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.semarthrit.2007.10.010","article-title":"The immunobiology of systemic sclerosis","volume":"38","author":"Guy","year":"2008","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.autrev.2015.10.001_bb0015","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1016\/j.autrev.2013.10.010","article-title":"Chemokine (C-X-C motif) ligand (CXCL)10 in autoimmune diseases","volume":"13","author":"Antonelli","year":"2014","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2015.10.001_bb0020","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/j.autrev.2014.12.001","article-title":"Vascular biomarkers and correlation with peripheral vasculopathy in systemic sclerosis","volume":"14","author":"Chora","year":"2015","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2015.10.001_bb0025","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1016\/j.autrev.2013.12.002","article-title":"Socioeconomic status. The relationship with health and autoimmune diseases","volume":"13","author":"Calixto","year":"2014","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2015.10.001_bb0030","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1016\/j.autrev.2015.07.012","article-title":"A review on quality of life in systemic sclerosis","volume":"14","author":"Almeida","year":"2015","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2015.10.001_bb0035","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.amjmed.2006.08.009","article-title":"The role of patient-centered outcomes in the course of chronic obstructive pulmonary disease: how long-term studies contribute to our understanding","volume":"119","author":"Tashkin","year":"2006","journal-title":"Am J Med"},{"key":"10.1016\/j.autrev.2015.10.001_bb0040","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.semarthrit.2007.05.003","article-title":"Incidence and prevalence of systemic sclerosis: a systematic literature review","volume":"37","author":"Chifflot","year":"2008","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.autrev.2015.10.001_bb0045","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1016\/j.autrev.2014.08.029","article-title":"Systemic sclerosis evolution of disease pathomorphosis and survival. Our experience on Italian patients' population and review of the literature","volume":"13","author":"Ferri","year":"2014","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2015.10.001_bb0050","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1016\/j.autrev.2014.07.003","article-title":"Serum free light chains of immunoglobulins as biomarkers for systemic sclerosis characteristics, activity and severity","volume":"13","author":"Lanteri","year":"2014","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2015.10.001_bb0055","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1016\/j.autrev.2014.08.016","article-title":"Systemic sclerosis and prevalence of monoclonal immunoglobulin","volume":"13","author":"Trad","year":"2014","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2015.10.001_bb0060","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1111\/j.1365-2249.2006.03041.x","article-title":"Peripheral T lymphocytes from patients with early systemic sclerosis co-cultured with autologous fibroblasts undergo an oligoclonal expansion similar to that occurring in the skin","volume":"144","author":"De Palma","year":"2006","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.autrev.2015.10.001_bb0065","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1016\/j.autrev.2012.05.011","article-title":"Autoantibodies in systemic sclerosis","volume":"12","author":"Mehra","year":"2013","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2015.10.001_bb0070","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/j.autrev.2010.09.025","article-title":"Historical perspectives on the discovery and elucidation of autoantibodies to centromere proteins (CENP) and the emerging importance of antibodies to CENP-F","volume":"10","author":"Fritzler","year":"2011","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2015.10.001_bb0075","doi-asserted-by":"crossref","first-page":"1937","DOI":"10.1016\/j.cca.2011.06.041","article-title":"Anti-centromere antibodies in a large cohort of systemic sclerosis patients: comparison between immunofluorescence, CENP-A and CENP-B ELISA","volume":"412","author":"Mahler","year":"2011","journal-title":"Clin Chim Acta"},{"key":"10.1016\/j.autrev.2015.10.001_bb0080","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.semarthrit.2005.03.005","article-title":"Autoantibodies in systemic sclerosis","volume":"35","author":"Steen","year":"2005","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.autrev.2015.10.001_bb0085","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1097\/BOR.0b013e3282e7d8f9","article-title":"Update on autoantibodies in systemic sclerosis","volume":"19","author":"Walker","year":"2007","journal-title":"Curr Opin Rheumatol"},{"key":"10.1016\/j.autrev.2015.10.001_bb0090","doi-asserted-by":"crossref","first-page":"R99","DOI":"10.1186\/ar3029","article-title":"Clinical and serological evaluation of a novel CENP-A peptide based ELISA","volume":"12","author":"Mahler","year":"2010","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.autrev.2015.10.001_bb0095","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1016\/0002-9343(80)90462-3","article-title":"The CREST syndrome: a distinct serologic entity with anticentromere antibodies","volume":"69","author":"Fritzler","year":"1980","journal-title":"Am J Med"},{"key":"10.1016\/j.autrev.2015.10.001_bb0100","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1002\/art.11113","article-title":"Evidence-based guidelines for the use of immunologic tests: anticentromere, Scl-70, and nucleolar antibodies","volume":"49","author":"Reveille","year":"2003","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2015.10.001_bb0105","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1136\/ard.2006.062901","article-title":"Clinical risk assessment of organ manifestations in systemic sclerosis: a report from the EULAR Scleroderma Trials and Research Group database","volume":"66","author":"Walker","year":"2007","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2015.10.001_bb0110","doi-asserted-by":"crossref","first-page":"2548","DOI":"10.3899\/jrheum.100402","article-title":"Anticentromere-A and anticentromere-B antibodies show high concordance and similar clinical associations in patients with systemic sclerosis","volume":"37","author":"Hanke","year":"2010","journal-title":"J Rheumatol"},{"key":"10.1016\/j.autrev.2015.10.001_bb0115","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1111\/j.1756-185X.2011.01688.x","article-title":"South Australian Scleroderma Register: autoantibodies as predictive biomarkers of phenotype and outcome","volume":"15","author":"Graf","year":"2012","journal-title":"Int J Rheum Dis"},{"key":"10.1016\/j.autrev.2015.10.001_bb0120","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1136\/annrheumdis-2011-200631","article-title":"Demographic, clinical and antibody characteristics of patients with digital ulcers in systemic sclerosis: data from the DUO Registry","volume":"71","author":"Denton","year":"2012","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2015.10.001_bb0125","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1097\/00005792-200203000-00004","article-title":"Systemic sclerosis: demographic, clinical, and serologic features and survival in 1,012 Italian patients","volume":"81","author":"Ferri","year":"2002","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.autrev.2015.10.001_bb0130","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1093\/rheumatology\/keg170","article-title":"The association of antinuclear antibodies with organ involvement and survival in systemic sclerosis","volume":"42","author":"Hesselstrand","year":"2003","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.autrev.2015.10.001_bb0135","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1002\/art.10760","article-title":"A comparison between anti-Th\/To- and anticentromere antibody-positive systemic sclerosis patients with limited cutaneous involvement","volume":"48","author":"Mitri","year":"2003","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2015.10.001_bb0140","doi-asserted-by":"crossref","first-page":"787","DOI":"10.3899\/rheum.111133","article-title":"Clinical correlates of CENP-A and CENP-B antibodies in a large cohort of patients with systemic sclerosis","volume":"39","author":"Hudson","year":"2012","journal-title":"J Rheumatol"},{"key":"10.1016\/j.autrev.2015.10.001_bb0145","doi-asserted-by":"crossref","first-page":"451","DOI":"10.2169\/internalmedicine.39.451","article-title":"Clinical, serological and genetic study in patients with CREST syndrome","volume":"39","author":"Akiyama","year":"2000","journal-title":"Intern Med"},{"key":"10.1016\/j.autrev.2015.10.001_bb0150","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1097\/00005792-200203000-00005","article-title":"Predicting mortality in systemic sclerosis: analysis of a cohort of 309 French Canadian patients with emphasis on features at diagnosis as predictive factors for survival","volume":"81","author":"Scussel-Lonzetti","year":"2002","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.autrev.2015.10.001_bb0155","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1002\/art.20065","article-title":"The TNF-863A allele strongly associates with anticentromere antibody positivity in scleroderma","volume":"50","author":"Sato","year":"2004","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2015.10.001_bb0160","doi-asserted-by":"crossref","first-page":"10514","DOI":"10.1016\/S0021-9258(19)86738-8","article-title":"Identification of a nuclear protein (Scl-70) as a unique target of human antinuclear antibodies in scleroderma","volume":"254","author":"Douvas","year":"1979","journal-title":"J Biol Chem"},{"key":"10.1016\/j.autrev.2015.10.001_bb0165","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1126\/science.3003910","article-title":"High titers of autoantibodies to topoisomerase I (Scl-70) in sera from scleroderma patients","volume":"231","author":"Shero","year":"1986","journal-title":"Science"},{"key":"10.1016\/j.autrev.2015.10.001_bb0170","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.clim.2006.12.003","article-title":"Immunoblotting on HEp-2 cells increases the detection of antitopoisomerase 1 antibodies in patients with systemic sclerosis","volume":"123","author":"Tamby","year":"2007","journal-title":"Clin Immunol"},{"key":"10.1016\/j.autrev.2015.10.001_bb0175","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1016\/j.autrev.2010.06.005","article-title":"Anti-Scl-70 (topo-I) antibodies in SLE: myth or reality?","volume":"9","author":"Mahler","year":"2010","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2015.10.001_bb0180","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1002\/art.10977","article-title":"Correlation of serum anti-DNA topoisomerase I antibody levels with disease severity and activity in systemic sclerosis","volume":"48","author":"Hu","year":"2003","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2015.10.001_bb0185","doi-asserted-by":"crossref","first-page":"3902","DOI":"10.1002\/art.24038","article-title":"Autoantibodies and microvascular damage are independent predictive factors for the progression of Raynaud's phenomenon to systemic sclerosis a twenty-year prospective study of 586 patients, with validation of proposed criteria for early systemic sclerosis","volume":"58","author":"Koenig","year":"2008","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2015.10.001_bb0190","doi-asserted-by":"crossref","first-page":"133","DOI":"10.2217\/bmm.09.79","article-title":"Biomarkers in systemic sclerosis","volume":"4","author":"Castro","year":"2010","journal-title":"Biomark Med"},{"key":"10.1016\/j.autrev.2015.10.001_bb0195","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1002\/art.1780350621","article-title":"Association of anti-topoisomerase I with cancer","volume":"35","author":"Rothfield","year":"1992","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2015.10.001_bb0200","first-page":"1994","article-title":"Autoantibodies in patients with systemic sclerosis and cancer: a case-control study","volume":"30","author":"Derk","year":"2003","journal-title":"J Rheumatol"},{"key":"10.1016\/j.autrev.2015.10.001_bb0205","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1016\/j.autrev.2014.03.003","article-title":"Systemic sclerosis, breast cancer and calcium channel blockers: a new player on the scene?","volume":"13","author":"Bernal-Bello","year":"2014","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2015.10.001_bb0210","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.autrev.2013.09.006","article-title":"Breast cancer in systemic sclerosis: results of a cross-linkage of an Italian rheumatologic center and a population-based cancer registry and review of the literature","volume":"13","author":"Colaci","year":"2014","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2015.10.001_bb0215","doi-asserted-by":"crossref","first-page":"167","DOI":"10.3389\/fimmu.2015.00167","article-title":"Autoantibodies in systemic sclerosis: unanswered questions","volume":"6","author":"Kayser","year":"2015","journal-title":"Front Immunol"},{"key":"10.1016\/j.autrev.2015.10.001_bb0220","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1046\/j.1365-2249.1999.00964.x","article-title":"Clinical and serological associations with anti-RNA polymerase antibodies in systemic sclerosis","volume":"117","author":"Harvey","year":"1999","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.autrev.2015.10.001_bb0225","first-page":"1528","article-title":"Antibodies to RNA polymerase III in systemic sclerosis detected by ELISA","volume":"34","author":"Santiago","year":"2007","journal-title":"J Rheumatol"},{"key":"10.1016\/j.autrev.2015.10.001_bb0230","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1016\/j.autrev.2009.02.002","article-title":"Anti-RNA polymerase III antibodies: a marker of systemic sclerosis with rapid onset and skin thickening progression","volume":"8","author":"Cavazzana","year":"2009","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2015.10.001_bb0235","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1172\/JCI116343","article-title":"Autoantibody reactive with three classes of RNA polymerases in sera from patients with systemic sclerosis","volume":"91","author":"Kuwana","year":"1993","journal-title":"J Clin Invest"},{"key":"10.1016\/j.autrev.2015.10.001_bb0240","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1093\/rheumatology\/kep290","article-title":"Clinical usefulness of anti-RNA polymerase III antibody measurement by enzyme-linked immunosorbent assay","volume":"48","author":"Satoh","year":"2009","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.autrev.2015.10.001_bb0245","doi-asserted-by":"crossref","first-page":"R211","DOI":"10.1186\/ar3544","article-title":"Prevalence, correlates and clinical usefulness of antibodies to RNA polymerase III in systemic sclerosis: a cross-sectional analysis of data from an Australian cohort","volume":"13","author":"Nikpour","year":"2011","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.autrev.2015.10.001_bb0250","doi-asserted-by":"crossref","first-page":"39","DOI":"10.3109\/03009742.2011.610032","article-title":"Scleroderma renal crisis in a Swedish systemic sclerosis cohort: survival, renal outcome, and RNA polymerase III antibodies as a risk factor","volume":"41","author":"Hesselstrand","year":"2012","journal-title":"Scand J Rheumatol"},{"key":"10.1016\/j.autrev.2015.10.001_bb0255","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1053\/sarh.2001.20268","article-title":"Systemic sclerosis in 3 US ethnic groups: a comparison of clinical, sociodemographic, serologic, and immunogenetic determinants","volume":"30","author":"Reveille","year":"2001","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.autrev.2015.10.001_bb0260","doi-asserted-by":"crossref","first-page":"3266","DOI":"10.1002\/art.10673","article-title":"Identity of the RNase MRP- and RNase P-associated Th\/To autoantigen","volume":"46","author":"Van","year":"2002","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2015.10.001_bb0265","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1016\/j.autrev.2014.11.007","article-title":"Autoantibodies to the mitochondrial RNA processing (MRP) complex also known as Th\/To autoantigen","volume":"14","author":"Mahler","year":"2015","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2015.10.001_bb0270","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1046\/j.1365-2249.2002.01991.x","article-title":"Autoantibodies against small nucleolar ribonucleoprotein complexes and their clinical associations","volume":"130","author":"Van","year":"2002","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.autrev.2015.10.001_bb0275","doi-asserted-by":"crossref","first-page":"1822","DOI":"10.1002\/art.1780331210","article-title":"Autoantibody to Th ribonucleoprotein (nucleolar 7-2 RNA protein particle) in patients with systemic sclerosis","volume":"33","author":"Okano","year":"1990","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2015.10.001_bb0280","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.autrev.2012.07.005","article-title":"Diagnostic accuracy and predictive value of extended autoantibody profile in systemic sclerosis","volume":"12","author":"Villalta","year":"2012","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2015.10.001_bb0285","doi-asserted-by":"crossref","first-page":"2071","DOI":"10.3899\/jrheum.100316","article-title":"Anti-Th\/To are common antinucleolar autoantibodies in Italian patients with scleroderma","volume":"37","author":"Ceribelli","year":"2010","journal-title":"J Rheumatol"},{"key":"10.1016\/j.autrev.2015.10.001_bb0290","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1016\/S0092-8674(00)80247-0","article-title":"Sno storm in the nucleolus: new roles for myriad small RNPs","volume":"89","author":"Smith","year":"1997","journal-title":"Cell"},{"key":"10.1016\/j.autrev.2015.10.001_bb0295","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1093\/rheumatology\/40.10.1157","article-title":"Anti-fibrillarin antibodies in systemic sclerosis","volume":"40","author":"Tormey","year":"2001","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.autrev.2015.10.001_bb0300","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1002\/art.21646","article-title":"DNA topoisomerase I binding to fibroblasts induces monocyte adhesion and activation in the presence of anti-topoisomerase I autoantibodies from systemic sclerosis patients","volume":"54","author":"Henault","year":"2006","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2015.10.001_bb0305","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1002\/art.24409","article-title":"Anti-U3 RNP autoantibodies in systemic sclerosis","volume":"60","author":"Aggarwal","year":"2009","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2015.10.001_bb0310","doi-asserted-by":"crossref","first-page":"1622","DOI":"10.3899\/jrheum.110071","article-title":"Anti-fibrillarin antibody in African American patients with systemic sclerosis: immunogenetics, clinical features, and survival analysis","volume":"38","author":"Sharif","year":"2011","journal-title":"J Rheumatol"},{"key":"10.1016\/j.autrev.2015.10.001_bb0315","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/S0968-0004(97)01018-9","article-title":"Pre-mRNA splicing: the discovery of a new spliceosome doubles the challenge","volume":"22","author":"Tarn","year":"1997","journal-title":"Trends Biochem Sci"},{"key":"10.1016\/j.autrev.2015.10.001_bb0320","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1093\/rheumatology\/37.1.39","article-title":"Clinical features and serum antinuclear antibodies in 230 Danish patients with systemic sclerosis","volume":"37","author":"Jacobsen","year":"1998","journal-title":"Br J Rheumatol"},{"key":"10.1016\/j.autrev.2015.10.001_bb0325","first-page":"104","article-title":"Disease subsets, antinuclear antibody profile, and clinical features in 127 French and 247 US adult patients with systemic sclerosis","volume":"34","author":"Meyer","year":"2007","journal-title":"J Rheumatol"},{"key":"10.1016\/j.autrev.2015.10.001_bb0330","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1016\/j.autrev.2006.08.007","article-title":"Anti-RNP immunity: implications for tissue injury and the pathogenesis of connective tissue disease","volume":"6","author":"Keith","year":"2007","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2015.10.001_bb0335","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1111\/j.1365-2133.2007.08392.x","article-title":"The clinical relevance of serum antinuclear antibodies in Japanese patients with systemic sclerosis","volume":"158","author":"Hamaguchi","year":"2008","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.autrev.2015.10.001_bb0340","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1046\/j.1523-1747.2003.12028.x","article-title":"The prevalence and clinical significance of anti-U1 RNA antibodies in patients with systemic sclerosis","volume":"120","author":"Asano","year":"2003","journal-title":"J Investig Dermatol"},{"key":"10.1016\/j.autrev.2015.10.001_bb0345","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1007\/s11926-004-0061-9","article-title":"Antibodies in scleroderma: direct pathogenicity and phenotypic associations","volume":"6","author":"Chung","year":"2004","journal-title":"Curr Rheumatol Rep"},{"key":"10.1016\/j.autrev.2015.10.001_bb0350","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1038\/nrrheum.2009.238","article-title":"Autoantibodies as predictive tools in systemic sclerosis","volume":"6","author":"Nihtyanova","year":"2010","journal-title":"Nat Rev Rheumatol"},{"key":"10.1016\/j.autrev.2015.10.001_bb0355","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1016\/j.autrev.2014.03.004","article-title":"The clinical phenotype associated with myositis-specific and associated autoantibodies: a meta-analysis revisiting the so-called antisynthetase syndrome","volume":"13","author":"Lega","year":"2014","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2015.10.001_bb0360","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1046\/j.1365-2249.1999.00961.x","article-title":"Distribution and antigen specificity of anti-U1RNP antibodies in patients with systemic sclerosis","volume":"117","author":"Ihn","year":"1999","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.autrev.2015.10.001_bb0365","first-page":"1511","article-title":"Clinical course of patients with anti-Rnp antibodies\u2014a prospective-study of 32 patients","volume":"18","author":"Lundberg","year":"1991","journal-title":"J Rheumatol"},{"key":"10.1016\/j.autrev.2015.10.001_bb0370","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1007\/978-1-4615-4857-7_12","article-title":"Scleroderma overlap syndromes","volume":"455","author":"Jablonska","year":"1999","journal-title":"Adv Exp Med Biol"},{"key":"10.1016\/j.autrev.2015.10.001_bb0375","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1002\/1529-0131(200004)43:4<881::AID-ANR20>3.0.CO;2-G","article-title":"Autoantibody recognition of distinctly modified forms of the U1-70-kd antigen is associated with different clinical disease manifestations","volume":"43","author":"Greidinger","year":"2000","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2015.10.001_bb0380","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.1128\/MCB.12.3.1276","article-title":"The low-abundance U11 and U12 small nuclear ribonucleoproteins (snRNPs) interact to form a two-snRNP complex","volume":"12","author":"Wassarman","year":"1992","journal-title":"Mol Cell Biol"},{"key":"10.1016\/j.autrev.2015.10.001_bb0385","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1002\/art.24586","article-title":"Anti-U11\/U12 RNP antibodies in systemic sclerosis: a new serologic marker associated with pulmonary fibrosis","volume":"61","author":"Fertig","year":"2009","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2015.10.001_bb0390","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1186\/ar389","article-title":"Autoantibodies directed to novel components of the PM\/Scl complex, the human exosome","volume":"4","author":"Brouwer","year":"2002","journal-title":"Arthritis Res"},{"key":"10.1016\/j.autrev.2015.10.001_bb0395","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1016\/j.autrev.2007.01.013","article-title":"Novel aspects of autoantibodies to the PM\/Scl complex: clinical, genetic and diagnostic insights","volume":"6","author":"Mahler","year":"2007","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2015.10.001_bb0400","doi-asserted-by":"crossref","first-page":"R704","DOI":"10.1186\/ar1729","article-title":"Clinical evaluation of autoantibodies to a novel PM\/Scl peptide antigen","volume":"7","author":"Mahler","year":"2005","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.autrev.2015.10.001_bb0405","doi-asserted-by":"crossref","first-page":"R22","DOI":"10.1186\/ar2614","article-title":"Antibodies against PM\/Scl-75 and PM\/Scl-100 are independent markers for different subsets of systemic sclerosis patients","volume":"11","author":"Hanke","year":"2009","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.autrev.2015.10.001_bb0410","doi-asserted-by":"crossref","first-page":"1608","DOI":"10.1002\/art.38428","article-title":"Clinical and serologic correlates of anti-PM\/Scl antibodies in systemic sclerosis: a multicenter study of 763 patients","volume":"66","author":"D'Aoust","year":"2014","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.autrev.2015.10.001_bb0415","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1186\/ar2646","article-title":"The changing landscape of the clinical value of the PM\/Scl autoantibody system","volume":"11","author":"Mahler","year":"2009","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.autrev.2015.10.001_bb0420","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/j.semarthrit.2014.07.002","article-title":"Good outcome of interstitial lung disease in patients with scleroderma associated to anti-PM\/Scl antibody","volume":"44","author":"Guillen-Del Castillo","year":"2014","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.autrev.2015.10.001_bb0425","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1002\/art.1780340111","article-title":"Prognostic significance of anticentromere antibodies and anti-topoisomerase I antibodies in Raynaud's disease. A prospective study","volume":"34","author":"Weiner","year":"1991","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2015.10.001_bb0430","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1002\/art.1780310207","article-title":"Clinical correlations and prognosis based on serum autoantibodies in patients with systemic sclerosis","volume":"31","author":"Steen","year":"1988","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2015.10.001_bb0435","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1093\/rheumatology\/ken179","article-title":"The registry of the German Network for Systemic Scleroderma: frequency of disease subsets and patterns of organ involvement","volume":"47","author":"Hunzelmann","year":"2008","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.autrev.2015.10.001_bb0440","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1002\/art.1780270201","article-title":"A long-term longitudinal study of anticentromere antibodies","volume":"27","author":"Tramposch","year":"1984","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2015.10.001_bb0445","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1016\/j.autrev.2008.06.010","article-title":"Predictive value of antinuclear autoantibodies: the lessons of the systemic sclerosis autoantibodies","volume":"7","author":"Koenig","year":"2008","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2015.10.001_bb0450","first-page":"1573","article-title":"Criteria for the classification of early systemic sclerosis","volume":"28","author":"LeRoy","year":"2001","journal-title":"J Rheumatol"},{"key":"10.1016\/j.autrev.2015.10.001_bb0455","doi-asserted-by":"crossref","first-page":"1520","DOI":"10.1002\/acr.22304","article-title":"Early systemic sclerosis: analysis of the disease course in patients with marker autoantibody and\/or capillaroscopic positivity","volume":"66","author":"Valentini","year":"2014","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"10.1016\/j.autrev.2015.10.001_bb0460","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1002\/art.1780280114","article-title":"Evolution of primary Raynaud's phenomenon (Raynaud's disease) to connective tissue disease","volume":"28","author":"Gerbracht","year":"1985","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2015.10.001_bb0465","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1016\/j.autrev.2013.12.001","article-title":"Raynaud's phenomenon: from molecular pathogenesis to therapy","volume":"13","author":"Prete","year":"2014","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2015.10.001_bb0470","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/j.autrev.2014.11.002","article-title":"Undifferentiated connective tissue disease at risk for systemic sclerosis (SSc) (so far referred to as very early\/early SSc or pre-SSc)","volume":"14","author":"Valentini","year":"2015","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2015.10.001_bb0475","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1002\/art.1780260714","article-title":"Anticentromere antibodies in primary biliary cirrhosis","volume":"26","author":"Makinen","year":"1983","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2015.10.001_bb0480","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1136\/ard.52.8.586","article-title":"Anticentromere antibodies in subjects with no apparent connective-tissue disease","volume":"52","author":"Lee","year":"1993","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2015.10.001_bb0485","first-page":"1643","article-title":"The pathogenic role of autoantibodies to nuclear autoantigens in systemic sclerosis (scleroderma)","volume":"32","author":"Senecal","year":"2005","journal-title":"J Rheumatol"},{"key":"10.1016\/j.autrev.2015.10.001_bb0490","doi-asserted-by":"crossref","first-page":"37","DOI":"10.7326\/0003-4819-140-2-200401200-00013","article-title":"Following the molecular pathways toward an understanding of the pathogenesis of systemic sclerosis","volume":"140","author":"Jimenez","year":"2004","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.autrev.2015.10.001_bb0495","doi-asserted-by":"crossref","first-page":"R285","DOI":"10.1016\/j.cub.2010.01.034","article-title":"Mechanisms of chromosomal instability","volume":"20","author":"Thompson","year":"2010","journal-title":"Curr Biol"},{"key":"10.1016\/j.autrev.2015.10.001_bb0500","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1038\/35084512","article-title":"Determining centromere identity: cyclical stories and forking paths","volume":"2","author":"Sullivan","year":"2001","journal-title":"Nat Rev Genet"},{"key":"10.1016\/j.autrev.2015.10.001_bb0505","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.clim.2010.06.008","article-title":"The immunodominant epitope of centromere-associated protein A displays homology with the transcription factor forkhead box E3 (FOXE3)","volume":"137","author":"Perosa","year":"2010","journal-title":"Clin Immunol"},{"key":"10.1016\/j.autrev.2015.10.001_bb0510","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0061453","article-title":"Autoantibodies recognizing the amino terminal 1-17 segment of CENP-A display unique specificities in systemic sclerosis","volume":"8","author":"Favoino","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.autrev.2015.10.001_bb0515","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1002\/art.1780330508","article-title":"Immunogenetic associations of scleroderma-related antinuclear antibodies","volume":"33","author":"Genth","year":"1990","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2015.10.001_bb0520","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1111\/j.1365-2249.1994.tb06552.x","article-title":"Anti-centromere antibodies (ACA) in systemic sclerosis patients and their relatives: a serological and HLA study","volume":"96","author":"McHugh","year":"1994","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.autrev.2015.10.001_bb0525","first-page":"80","article-title":"The clinical relevance of autoantibodies in scleroderma","volume":"5","author":"Ho","year":"2003","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.autrev.2015.10.001_bb0530","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1002\/1529-0131(200005)43:5<1074::AID-ANR18>3.0.CO;2-E","article-title":"Longitudinal analysis of autoantibody response to topoisomerase I in systemic sclerosis","volume":"43","author":"Kuwana","year":"2000","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2015.10.001_bb0535","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1016\/j.autrev.2009.02.018","article-title":"Anti-topoisomerase I autoantibodies in systemic sclerosis","volume":"8","author":"Czompoly","year":"2009","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2015.10.001_bb0540","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1016\/j.autrev.2011.03.001","article-title":"Autoantibodies to intracellular antigens: generation and pathogenetic role","volume":"10","author":"Racanelli","year":"2011","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2015.10.001_bb0545","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/0092-8674(83)90236-2","article-title":"Human anticentromere antibodies: distribution, characterization of antigens, and effect on microtubule organization","volume":"35","author":"Cox","year":"1983","journal-title":"Cell"},{"key":"10.1016\/j.autrev.2015.10.001_bb0550","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1083\/jcb.111.4.1519","article-title":"Injection of anticentromere antibodies in interphase disrupts events required for chromosome movement at mitosis","volume":"111","author":"Bernat","year":"1990","journal-title":"J Cell Biol"},{"key":"10.1016\/j.autrev.2015.10.001_bb0555","doi-asserted-by":"crossref","first-page":"2216","DOI":"10.1002\/art.24715","article-title":"Apoptotic cell blebs: repositories of autoantigens and contributors to immune context","volume":"60","author":"Suber","year":"2009","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2015.10.001_bb0560","doi-asserted-by":"crossref","first-page":"7266","DOI":"10.1073\/pnas.130189697","article-title":"Human centromere protein A (CENP-A) can replace histone H3 in nucleosome reconstitution in vitro","volume":"97","author":"Yoda","year":"2000","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.autrev.2015.10.001_bb0565","doi-asserted-by":"crossref","first-page":"34","DOI":"10.4161\/epi.5.1.10629","article-title":"Centromeres: the wild west of the post-genomic age","volume":"5","author":"Zeitlin","year":"2010","journal-title":"Epigenetics"},{"key":"10.1016\/j.autrev.2015.10.001_bb0570","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1046\/j.1365-2249.2000.01189.x","article-title":"Autoepitopes on autoantigen centromere protein-A (CENP-A) are restricted to the N-terminal region, which has no homology with histone H3","volume":"120","author":"Muro","year":"2000","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.autrev.2015.10.001_bb0575","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1016\/j.jaut.2006.10.001","article-title":"Fine specificity mapping of autoantigens targeted by anti-centromere autoantibodies","volume":"27","author":"Akbarali","year":"2006","journal-title":"J Autoimmun"},{"key":"10.1016\/j.autrev.2015.10.001_bb0580","doi-asserted-by":"crossref","first-page":"R72","DOI":"10.1186\/ar4249","article-title":"Clinical correlates of a subset of anti-CENP-A antibodies cross-reacting with FOXE3p53-62 in systemic sclerosis","volume":"15","author":"Perosa","year":"2013","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.autrev.2015.10.001_bb0585","doi-asserted-by":"crossref","first-page":"416","DOI":"10.4049\/jimmunol.182.1.416","article-title":"Two structurally different rituximab-specific CD20 mimotope peptides reveal that rituximab recognizes two different CD20-associated epitopes","volume":"182","author":"Perosa","year":"2009","journal-title":"J Immunol"},{"key":"10.1016\/j.autrev.2015.10.001_bb0590","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1007\/s001090000128","article-title":"Fine-specificity of the anti-CENP-A B-cell autoimmune response","volume":"78","author":"Mahler","year":"2000","journal-title":"J Mol Med"},{"key":"10.1016\/j.autrev.2015.10.001_bb0595","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1007\/s001090100258","article-title":"A population of autoantibodies against a centromere-associated protein A major epitope motif cross-reacts with related cryptic epitopes on other nuclear autoantigens and on the Epstein-Barr nuclear antigen 1","volume":"79","author":"Mahler","year":"2001","journal-title":"J Mol Med"},{"key":"10.1016\/j.autrev.2015.10.001_bb0600","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1083\/jcb.127.3.581","article-title":"Human CENP-A contains a histone H3 related histone fold domain that is required for targeting to the centromere","volume":"127","author":"Sullivan","year":"1994","journal-title":"J Cell Biol"},{"key":"10.1016\/j.autrev.2015.10.001_bb0605","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1182\/blood-2005-04-1769","article-title":"Generation of biologically active linear and cyclic peptides has revealed a unique fine specificity of rituximab and its possible cross-reactivity with acid sphingomyelinase-like phosphodiesterase 3b precursor","volume":"107","author":"Perosa","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.autrev.2015.10.001_bb0610","doi-asserted-by":"crossref","first-page":"1918","DOI":"10.4049\/jimmunol.171.4.1918","article-title":"Beta 2-microglobulin-free HLA class I heavy chain epitope mimicry by monoclonal antibody HC-10-specific peptide","volume":"171","author":"Perosa","year":"2003","journal-title":"J Immunol"},{"key":"10.1016\/j.autrev.2015.10.001_bb0615","doi-asserted-by":"crossref","first-page":"7967","DOI":"10.4049\/jimmunol.179.11.7967","article-title":"Identification of an antigenic and immunogenic motif expressed by two 7-mer rituximab-specific cyclic peptide mimotopes: implication for peptide-based active immunotherapy","volume":"179","author":"Perosa","year":"2007","journal-title":"J Immunol"},{"key":"10.1016\/j.autrev.2015.10.001_bb0620","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1136\/annrheumdis-2015-eular.2398","article-title":"Subspecificities of anti-centromeric-associated protein A (CENP-A) antibodies (Ab) can identified a subset of patients at higher risk of developing pulmonary hypertension","volume":"74","author":"Favoino","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2015.10.001_bb0625","doi-asserted-by":"crossref","first-page":"A259","DOI":"10.1016\/j.autrev.2009.12.002","article-title":"Definition of human autoimmunity--autoantibodies versus autoimmune disease","volume":"9","author":"Lleo","year":"2010","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2015.10.001_bb0630","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1016\/j.autrev.2012.02.006","article-title":"Intravenous immunoglobulin: exploiting the potential of natural antibodies","volume":"11","author":"Kaveri","year":"2012","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2015.10.001_bb0635","article-title":"ShRNA-targeted centromere protein A inhibits hepatocellular carcinoma growth","volume":"6","author":"Li","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.autrev.2015.10.001_bb0640","first-page":"3511","article-title":"Overexpression and mistargeting of centromere protein-A in human primary colorectal cancer","volume":"63","author":"Tomonaga","year":"2003","journal-title":"Cancer Res"},{"key":"10.1016\/j.autrev.2015.10.001_bb0645","doi-asserted-by":"crossref","first-page":"R72","DOI":"10.1186\/bcr3181","article-title":"Centromere protein-A, an essential centromere protein, is a prognostic marker for relapse in estrogen receptor-positive breast cancer","volume":"14","author":"McGovern","year":"2012","journal-title":"Breast Cancer Res"},{"key":"10.1016\/j.autrev.2015.10.001_bb0650","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1101\/gad.14.2.245","article-title":"A forkhead gene, FoxE3, is essential for lens epithelial proliferation and closure of the lens vesicle","volume":"14","author":"Blixt","year":"2000","journal-title":"Genes Dev"},{"key":"10.1016\/j.autrev.2015.10.001_bb0655","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1242\/dev.000117","article-title":"Foxe view of lens development and disease","volume":"134","author":"Medina-Martinez","year":"2007","journal-title":"Development"},{"key":"10.1016\/j.autrev.2015.10.001_bb0660","doi-asserted-by":"crossref","first-page":"4269","DOI":"10.1167\/iovs.08-2243","article-title":"Persistent FoxE3 expression blocks cytoskeletal remodeling and organelle degradation during lens fiber differentiation","volume":"49","author":"Landgren","year":"2008","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.autrev.2015.10.001_bb0665","first-page":"3413","article-title":"Expression of platelet-derived growth factor receptors in the developing chicken lens","volume":"35","author":"Potts","year":"1994","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.autrev.2015.10.001_bb0670","doi-asserted-by":"crossref","first-page":"4425","DOI":"10.1242\/dev.128.22.4425","article-title":"Fgf receptor signaling plays a role in lens induction","volume":"128","author":"Faber","year":"2001","journal-title":"Development"},{"key":"10.1016\/j.autrev.2015.10.001_bb0675","doi-asserted-by":"crossref","first-page":"1989","DOI":"10.1056\/NEJMra0806188","article-title":"Scleroderma","volume":"360","author":"Gabrielli","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.autrev.2015.10.001_bb0680","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1097\/01.bor.0000139310.77347.9c","article-title":"Cellular origins of fibroblasts: possible implications for organ fibrosis in systemic sclerosis","volume":"16","author":"Postlethwaite","year":"2004","journal-title":"Curr Opin Rheumatol"},{"key":"10.1016\/j.autrev.2015.10.001_bb0685","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1136\/annrheumdis-2014-eular.4130","article-title":"Expression of the transcription factor Forkhead Box E3 (Foxe3) in monocytes from patients with systemic sclerosis and correlation with their serological profile","volume":"73","author":"Favoino","year":"2014","journal-title":"Ann Rheum Dis"}],"container-title":["Autoimmunity Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1568997215002025?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1568997215002025?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,5,23]],"date-time":"2022-05-23T08:10:46Z","timestamp":1653293446000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1568997215002025"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,1]]},"references-count":137,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2016,1]]}},"alternative-id":["S1568997215002025"],"URL":"https:\/\/doi.org\/10.1016\/j.autrev.2015.10.001","relation":{},"ISSN":["1568-9972"],"issn-type":[{"value":"1568-9972","type":"print"}],"subject":[],"published":{"date-parts":[[2016,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Anti-centromere protein A antibodies in systemic sclerosis: Significance and origin","name":"articletitle","label":"Article Title"},{"value":"Autoimmunity Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.autrev.2015.10.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}